Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Multidrug-resistant tuberculosis in Europe, 2010–2011

Tools
- Tools
+ Tools

Günther, Gunar, van Leth, Frank, Alexandru, Sofia, Altet, Neus, Avsar, Korkut, Bang, Didi, Barbuta, Raisa, Bothamley, Graham, Ciobanu, Ana, Crudu, Valeriu et al.
(2015) Multidrug-resistant tuberculosis in Europe, 2010–2011. Emerging Infectious Diseases , Volume 21 (Number 3). pp. 409-416. doi:10.3201/eid2103.141343

Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.3201/eid2103.141343

Request Changes to record.

Abstract

Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non–MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010–2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to ≥1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fluoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.

Item Type: Journal Article
Divisions: Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Microbiology & Infection
Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine
Faculty of Medicine > Warwick Medical School
Journal or Publication Title: Emerging Infectious Diseases
Publisher: US Department of Health and Human Services
ISSN: 1080-6059
Official Date: March 2015
Dates:
DateEvent
March 2015Published
Volume: Volume 21
Number: Number 3
Page Range: pp. 409-416
DOI: 10.3201/eid2103.141343
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us